The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy

被引：4

作者：

Smith, Michael A. ^{[1
]}

Love, Bryan L. ^{[2
]}

Mohammad, Rima A. ^{[3
]}

机构：

[1] Univ Sci, Clin Pharm, Philadelphia Coll Pharm, Dept Pharm Practice & Pharm Adm, Philadelphia, PA USA

[2] South Carolina Coll Pharm, GI Hepatol, WJB Dorn VAMC, Dept Clin Pharm & Outcomes Sci, Columbia, SC USA

[3] Univ Michigan, Coll Pharm, Gen Surg Nutr, Univ Michigan Hlth Syst,Dept Clin Pharm, Ann Arbor, MI 48109 USA

来源：

EXPERT OPINION ON DRUG SAFETY | 2015年 / 14卷 / 11期

关键词：

adverse drug events; hepatitis C virus; ledipasvir; sofosbuvir; COMBINATION THERAPY; GENOTYPE; INFECTION; RIBAVIRIN; GRAZOPREVIR; SOFOSBUVIR; INTERFERON;

D O I：

10.1517/14740338.2015.1088002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Treatment of chronic hepatitis C virus (HCV) therapy has rapidly changed since the approval of IFN in the 1990s. Early treatment brought about significant and therapy limiting adverse drug events (ADEs) such as anemia. Since the direct-acting antivirals were first approved in 2011 and then advanced in 2013, treatment-related ADEs and therapy discontinuations have rapidly decreased, while sustained virologic response rates have significantly increased. As the market for treating chronic HCV therapy has changed, so too has the ADE profile clinicians may need to manage.

引用

页码：1649 / 1652

页数：4

共 16 条

[1] ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection [J].

Andreone, Pietro ;

Colombo, Massimo G. ;

Enejosa, Jeffrey V. ;

Koksal, Iftihar ;

Ferenci, Peter ;

Maieron, Andreas ;

Muellhaupt, Beat ;

Horsmans, Yves ;

Weiland, Ola ;

Reesink, Henk W. ;

Rodrigues, Lino, Jr. ;

Hu, Yiran B. ;

Podsadecki, Thomas ;

Bernstein, Barry .

GASTROENTEROLOGY, 2014, 147 (02) :359-+

[2]

[Anonymous], REC TEST MAN TREAT H

[3] Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin [J].

Feld, Jordan J. ;

Kowdley, Kris V. ;

Coakley, Eoin ;

Sigal, Samuel ;

Nelson, David R. ;

Crawford, Darrell ;

Weiland, Ola ;

Aguilar, Humberto ;

Xiong, Junyuan ;

Pilot-Matias, Tami ;

DaSilva-Tillmann, Barbara ;

Larsen, Lois ;

Podsadecki, Thomas ;

Bernstein, Barry .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (17) :1594-1603

[4] ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV [J].

Ferenci, Peter ;

Bernstein, David ;

Lalezari, Jacob ;

Cohen, Daniel ;

Luo, Yan ;

Cooper, Curtis ;

Tam, Edward ;

Marinho, Rui T. ;

Tsai, Naoky ;

Nyberg, Anders ;

Box, Terry D. ;

Younes, Ziad ;

Enayati, Pedram ;

Green, Sinikka ;

Baruch, Yaacov ;

Bhandari, Bal Raj ;

Caruntu, Florin Alexandru ;

Sepe, Thomas ;

Chulanov, Vladimir ;

Janczewska, Ewa ;

Rizzardini, Giuliano ;

Gervain, Judit ;

Planas, Ramon ;

Moreno, Christophe ;

Hassanein, Tarek ;

Xie, Wangang ;

King, Martin ;

Podsadecki, Thomas ;

Reddy, K. Rajender .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (21) :1983-1992

[5] Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent [J].

Forns, Xavier ;

Gordon, Stuart C. ;

Zuckerman, Eli ;

Lawitz, Eric ;

Calleja, Jose L. ;

Hofer, Harald ;

Gilbert, Christopher ;

Palcza, John ;

Howe, Anita Y. M. ;

DiNubile, Mark J. ;

Robertson, Michael N. ;

Wahl, Janice ;

Barr, Eliav ;

Buti, Maria .

JOURNAL OF HEPATOLOGY, 2015, 63 (03) :564-572

[6] Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C [J].

Hauser, Goran ;

Awad, Tahany ;

Brok, Jesper ;

Thorlund, Kristian ;

Stimac, Davor ;

Mabrouk, Mahasen ;

Gluud, Christian ;

Gluud, Lise Lotte .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (02)

[7] Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options [J].

Jacobson, Ira M. ;

Gordon, Stuart C. ;

Kowdley, Kris V. ;

Yoshida, Eric M. ;

Rodriguez-Torres, Maribel ;

Sulkowski, Mark S. ;

Shiffman, Mitchell L. ;

Lawitz, Eric ;

Everson, Gregory ;

Bennett, Michael ;

Schiff, Eugene ;

Al-Assi, M. Tarek ;

Subramanian, G. Mani ;

An, Di ;

Lin, Ming ;

McNally, John ;

Brainard, Diana ;

Symonds, William T. ;

McHutchison, John G. ;

Patel, Keyur ;

Feld, Jordan ;

Pianko, Stephen ;

Nelson, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (20) :1867-1877

[8] Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study [J].

Lawitz, Eric ;

Sulkowski, Mark S. ;

Ghalib, Reem ;

Rodriguez-Torres, Maribel ;

Younossi, Zobair M. ;

Corregidor, Ana ;

DeJesus, Edwin ;

Pearlman, Brian ;

Rabinovitz, Mordechai ;

Gitlin, Norman ;

Lim, Joseph K. ;

Pockros, Paul J. ;

Scott, John D. ;

Fevery, Bart ;

Lambrecht, Tom ;

Ouwerkerk-Mahadevan, Sivi ;

Callewaert, Katleen ;

Symonds, William T. ;

Picchio, Gaston ;

Lindsay, Karen L. ;

Beumont, Maria ;

Jacobson, Ira M. .

LANCET, 2014, 384 (9956) :1756-1765

[9]

Lawitz E, 2013, NEW ENGL J MED, V369, P678, DOI [10.1056/NEJMoa1214853, 10.1056/NEJMc1307641]

[10] ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS [J].

Manns, M. ;

Pol, S. ;

Jacobson, I. ;

Marcellin, P. ;

Gordon, S. ;

Peng, C. -Y. ;

Chang, T. -T. ;

Everson, G. ;

Heo, J. ;

Gerken, G. ;

Yoffe, B. ;

Towner, W. J. ;

Bourliere, M. ;

Metivier, S. ;

Chu, C. -J. ;

Sievert, W. ;

Bronowicki, J. -P. ;

Thabut, D. ;

Lee, Y. -J. ;

Kao, J. -H. ;

McPhee, F. ;

Kopit, J. ;

Mendez, P. ;

Linaberry, M. ;

Hughes, E. ;

Noviello, S. .

JOURNAL OF HEPATOLOGY, 2014, 60 (01) :S524-S525

← 1 2 →